Fragile X Syndrome Clinical Trial
Official title:
An Open-label Study to Evaluate the Long-term Safety and Tolerability of AFQ056 in Adolescent Patients With Fragile X Syndrome
The purpose of this study is to generate long-term safety, tolerability and efficacy data for AFQ056 in eligible adolescent patients with FXS who have participated in the CAFQ056B2214 study, the PK study CAFQ056B2131, or another study of AFQ056 which included FXS patients below 18 years of age provided the patient is at least 12 years of age at the time of entry into the current study.
Status | Terminated |
Enrollment | 119 |
Est. completion date | September 2014 |
Est. primary completion date | September 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 12 Years to 18 Years |
Eligibility |
Inclusion Criteria: - Group 1 patients: - Must have completed study CAFQ056B2214 or another study of AFQ056 which included FXS patients below 18 years of age within one week of enrollment into the open-label study. - Has a caregiver or caregivers who spend, on average, at least 6 hours per day with the patient , who is willing to and capable of supervising treatment, providing input into efficacy and safety assessments, and accompanying the patient to study visits. - Group 2 patients: - Must meet one of the following conditions: - Completed Study CAFQ056B2131 - Completed Study CAFQ056B2214 or another study of AFQ056 which included FXS patients below 18 years of age but enrollment into the current study was delayed for more than a week. - Discontinued prematurely from Study CAFQ056B2214 or another study of AFQ056 which included FXS patients below 18 years of age due to intolerability of the dosage in the patient's assigned treatment group. - Has a caregiver or caregivers who spend, on average, at least 6 hours per day with the patient , who is willing to and capable of supervising treatment, providing input into efficacy and safety assessments, and accompanying the patient to study visits. Exclusion Criteria: - Discontinuation from Study CAFQ056B2214 or CAFQ056B2131 or another study of AFQ056 which included FXS patients below 18 years of age due to safety reasons - Female patients who are sexually active at any time during the study - Any advanced, severe or unstable disease - History and/or presence of schizophrenia, bipolar disease, psychosis, confusional states and/or repeated hallucinations as per DSM-IV criteria - History of suicidal behavior or considered a high suicidal risk - History of severe self-injurious behavior - History of uncontrolled seizure disorder or resistant to therapy within the past 2 years (Patients who are clinically stable under anti-convulsant therapy for the past 2 years are not excluded) - History of clinically significant allergies requiring hospitalization or non-inhaled corticosteroid therapy (asthma, anaphylaxis, etc.) - History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether or not there is evidence of local recurrence or metastases - Patients who are using (or used within 6 weeks before baseline) digoxin or warfarin - Using (or used within 6 weeks before baseline) concomitant medications that are potent inhibitors or inducers of CYP3A4 - Using glutamatergic agents (riluzole, memantine, etc.) or lithium within 6 weeks of baseline Other protocol-defined inclusion/exclusion criteria may apply. |
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Australia | Novartis Investigative Site | Parkville | Victoria |
Australia | Novartis Investigative Site | Westmead | New South Wales |
Belgium | Novartis Investigative Site | Bruxelles | |
Belgium | Novartis Investigative Site | Leuven | |
Denmark | Novartis Investigative Site | Glostrup | |
France | Novartis Investigative Site | Bron Cedex | |
Germany | Novartis Investigative Site | Mainz | |
Germany | Novartis Investigative Site | München | |
Germany | Novartis Investigative Site | Tübingen | |
Germany | Novartis Investigative Site | Würzburg | |
Israel | Novartis Investigative Site | Ramat Gan | |
Italy | Novartis Investigative Site | Genova | GE |
Italy | Novartis Investigative Site | Padova | |
Netherlands | Novartis Investigative Site | Rotterdam | |
Spain | Novartis Investigative Site | Málaga | Andalucia |
Spain | Novartis Investigative Site | Sabadell | Barcelona |
Spain | Novartis Investigative Site | Sant Cugat | Cataluña |
Sweden | Novartis Investigative Site | Spånga | |
Switzerland | Novartis Investigative Site | Lausanne | |
Switzerland | Novartis Investigative Site | Zurich | |
United Kingdom | Novartis Investigative Site | Edinburgh | |
United States | Novartis Investigative Site | Boston | Massachusetts |
United States | Novartis Investigative Site | Chicago | Illinois |
United States | Novartis Investigative Site | Decatur | Georgia |
United States | Novartis Investigative Site | Nashville | Tennessee |
United States | Novartis Investigative Site | Omaha | Nebraska |
United States | Novartis Investigative Site | Sacramento | California |
United States | Novartis Investigative Site | Staten Island | New York |
Lead Sponsor | Collaborator |
---|---|
Novartis Pharmaceuticals |
United States, Australia, Belgium, Denmark, France, Germany, Israel, Italy, Netherlands, Spain, Sweden, Switzerland, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) | Adverse events were summarized for the open-label treatment period, where the open-label treatment period is defined based on how AEs were collected and reported according to the manner in which participants entered the current study and which treatment (AFQ056 or placebo) they were receiving in the previous study. AEs which were continuing from the core study or that started after the end of core study but prior to first dose of open-label study medication in the extension study for Category 1 participants are shown under 'Prior to Ext. first dose'. AEs which started during the open-label treatment period are presented based on the last AFQ056 dose taken on or before the onset date of the AE (25 mg bid; 50 mg bid; 75 mg bid; or 100 mg bid). No efficacy data presented as study was terminated. |
Prior to first dose in extension study, Baseline (start of study treatment in extension study) to End of trial | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05418049 -
Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge
|
Phase 2 | |
Enrolling by invitation |
NCT01364818 -
Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment
|
N/A | |
Completed |
NCT01120626 -
Randomized Controlled Study of Donepezil in Fragile X Syndrome
|
Phase 2 | |
Completed |
NCT00965432 -
A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107
|
Phase 1 | |
Completed |
NCT01204151 -
Teaching Math Skills to Individuals With Fragile X Syndrome
|
N/A | |
Active, not recruiting |
NCT00334971 -
Aromatase Activity and Ovarian Growth Factors in African-American Versus Caucasian Women
|
N/A | |
Enrolling by invitation |
NCT06139172 -
Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities
|
N/A | |
Recruiting |
NCT04977986 -
Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome
|
Phase 3 | |
Active, not recruiting |
NCT04698551 -
NIPD on cffDNA for Triplet Repeat Diseases
|
||
Completed |
NCT03722290 -
Metformin in Children and Adults With Fragile X Syndrome
|
Phase 2 | |
Completed |
NCT05030129 -
Single Blind Study of Ergoloid Mesylates, 5-HTP and the Combination in Adult Males With Fragile X Syndrome
|
Phase 2 | |
Recruiting |
NCT05957549 -
Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG
|
N/A | |
Recruiting |
NCT04141163 -
Metformin in Patients With Fragile X
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06081348 -
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
|
Phase 2 | |
Completed |
NCT00858689 -
Add-on Pilot Trial of Minocycline to Treat Fragile X Syndrome
|
N/A | |
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
Enrolling by invitation |
NCT03802799 -
Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS
|
Phase 2/Phase 3 | |
Recruiting |
NCT05295277 -
Validation of Optical Genome Mapping for the Identification of Constitutional Genomic Variants in a Postnatal Cohort
|
||
Enrolling by invitation |
NCT03836300 -
Parent and Infant Inter(X)Action Intervention (PIXI)
|
N/A | |
Completed |
NCT01725152 -
Ganaxolone Treatment in Children With Fragile X Syndrome
|
Phase 2 |